<DOC>
	<DOCNO>NCT01653990</DOCNO>
	<brief_summary>A single-center , randomize , double-blinded , 2-way crossover , placebo-controlled study ass QTc interval administration single oral dose 400mg Moxifloxacin healthy Chinese subject .</brief_summary>
	<brief_title>Moxifloxacin_QT Study Chinese Healthy Volunteer</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy Chinese subject , male , 20 45 year age include , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . 2 . At Screening , vital sign ( systolic diastolic blood pressure pulse rate ) assess sit position subject rest 5 minute . All vital sign within normal range : Body temperature ( Body ) 35.037.0°C 90 ≤ systolic blood pressure &lt; 140 mm Hg 60≤ diastolic blood pressure &lt; 90 mm Hg 50≤ pulse rate ≤ 100 3 . Body weight need least 50kg , 19kg/m2≤ Body Mass Index ( BMI ) ≤25kg/m2 4 . Be able communicate well investigator , understand comply requirement study . Understand sign write informed consent prior screen procedure . 1 . History clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , genetic psychiatric disorder . 2 . A past medical history clinically significant ECG abnormality family history ( grandparent , parent sibling ) long QT syndrome , QTc interval &gt; 440 m male abnormal ECG finding screen . 3 . Medical history syncope , electrophysiological change , heart failure , reduce exercise tolerance , cardiomyopathy , pericarditis , myocarditis cardiac disorder determine investigator . 4 . Current electrolyte abnormality ( specifically hypokalemia ) laboratory examination screen clinical significant determine investigator . 5 . Current recent history ( &lt; 30 day prior Screening ) clinically significant illness . 6 . Use prescription drug , herbal supplement , within 4 week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within 4 week prior initial dosing . 7 . Positive result human immunodeficiency virus , Hepatitis B surface antigen Hepatitis C antibody test . 8 . History hypersensitivity allergic reaction moxifloxacin type fluoroquinolones . 9 . Use tobacco history use tobacco ( &gt; 5 tobacco/week ) nicotinecontaining product 3 month prior screen . 10 . History drug alcohol abuse within 12 month prior dose , evidence abuse indicate laboratory assay conduct screen and/or baseline . 11 . Dosing study drug clinical investigation within 3 month prior initial dosing . 12 . Donation loss 200 ml blood within 3 month prior participation , donation component blood within 3 month prior participation . 13 . Consumption alcohol , caffeine contain food beverage within 48 hour precede study drug administration . 14 . Other condition investigator deem potential harm subject participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>